Komal Jhaveri, MD, FACP

Dr Jhaveri on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer

September 9th 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

August 22nd 2024

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Dr Jhaveri on the Evolution of Treatment With ADCs in HER2-Expressing Breast Cancer

July 17th 2024

Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Dr Jhaveri on the Implications of DESTINY-Breast06 for HR+/HER2-Low and -Ultralow Breast Cancer

July 1st 2024

Komal Jhaveri, MD, FACP, discusses the implications of the DESTINY-Breast06 trial for hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer

June 7th 2024

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.

Dr Jhaveri on the Rationale for the ELAINE-3 Trial in ESR1-Mutant ER+/HER2– Breast Cancer

December 21st 2023

Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr Jhaveri on Unanswered Questions in Breast Cancer Care

November 16th 2023

Komal Jhaveri, MD, FACP, discusses unmet needs for patients with breast cancer, as well as ways to address these needs through discussion and collaboration.

Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer

November 10th 2023

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

Looking Towards The Future of HR+/HER2- Breast Cancer

August 22nd 2023

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Practical Considerations for ADC Selection in HR+/HER2- mBC

August 22nd 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

Data Updates on Sacituzumab Govitecan

August 15th 2023

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.

Biomarker Testing Practices in HR+/HER2- Breast Cancer

August 15th 2023

Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

August 8th 2023

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Addressing Disease Progression on ET: Data Updates and Ongoing Trials

August 8th 2023

A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.

Potential Approaches to Treatment Switching in HR+/HER2- mBC

August 1st 2023

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice

August 1st 2023

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.

The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings

July 25th 2023

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials

July 25th 2023

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting

July 18th 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer

July 18th 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.